PCSANM's Position on US Preventative Services Task Force Revised Guideline on Prostate Cancer Screening
However, while PCSANM is pleased with the “C” recommendation embodied in the guidelines, there are weaknesses and omissions. Why a “C” but only for men 55-69? Just because the retrospective studies to date have looked more at that age group than others ignores the fact that because prostate cancer is often slow-growing, one doesn’t see the benefits of screening sometimes for more than 10-15 years. Screening early means fewer chances of developing metastatic disease during those years, so why wait until 55 to start testing? We believe that a man’s first, baseline PSA should be around the age of 45, establishing risk and personalizing future follow up. That risk stratification is critical. PSA is just a data point; it is what you do with that information that is important.
Why does the USPSTF (that worries about over treatment if a man is diagnosed) not recommend genomic testing, MRI, liquid biopsies, and other indolent disease that might lead to active surveillance rather than treatment? Why stop testing at age 70 and classify that as a “D” recommendation? Both the American Cancer Society and National Comprehensive Cancer Network talk about testing for men with at least a ten-year life expectancy– that should be the criterion, not an arbitrary age marker. And veterans, especially those who were exposed to Agent Orange, should be included in the “higher risk” population for earlier testing, along with African-American men and men with a positive family history.
US Preventative Services Task Force (USPSTF) Revised Guideline on Prostate Cancer Screening
US Preventive Services Task Force "C" Grade for Prostate Cancer Testing
Offer or provide this service for selected patients depending on individual circumstances.
Treatment is described as the "single biggest change in the last 20 years"
Rates of active surveillance still relatively low
Radiation therapy has the greatest impact on patient finances.
Shorter dosing interval, fewer teeth, use of dentures, and current smoking were associated with increased risk.
Validation of a Prognostic Genomic Classifier in Salvage Radiotherapy Prostate Cancer from a Prospective Randomized Trial
Alicia Morgans is joined by Felix Feng to discuss his recent presentation on a new analysis from a Phase III trial.
Prostate cancer is a multifocal disease, but if and how individual prostate tumours influence each other is largely unknown.
Antibody Profiling of Patients with Prostate Cancer Reveals Differences in Antibody Signatures Among Disease Stages
From the Journal for Immunotherapy of Cancer, as posted on Uro Today
Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
As treatment delays become more common – especially with the COVID-19 pandemic – delays as much as four weeks can impact the risk for mortality in seven different types of cancer.
From the Society of Urologic Oncology (SUO) 21st Annual Meeting